A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

NCT05872022 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing the safety of the medication Wegovy in pregnant individuals who are overweight or obese to see how it may affect their babies.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 728 people Planned (estimated).

Who can join Ages 15–50 · female only

Timeline Started 2023-07 · est. completion 2032-12

Where 3 sites · Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT05872022 ↗

Description as written by the study sponsor.

This is an observational, prospective Wegovy (semaglutide 2.4 milligram \[mg\]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.

Treatments tested

No Intervention Other

This is a non-interventional study, therefore no intervention is used.

Main thing measured	Number of Infants with Major Congenital Malformation (MCM)
Sponsor	Novo Nordisk A/S
Conditions studied	Pregnancy, Obesity, Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05872022 ↗